Research
Hormonal
Multiple incretin pharmaceutical agents show promise in the prevention and treatment of T2D.
Stay informed about new incretin agents for T2D prevention and treatment.
StrongSupportsmedium confidence
Finally, multiple incretin pharmaceutical agents have been developed that show promise in the prevention and treatment of T2D.
Why this rating
The claim is based on recent developments in pharmaceutical research.
Source
Trending Modalities in Type 2 Diabetes Prevention
Erika L. Lundgrin et al. · The Journal of Clinical Endocrinology & Metabolism · 2025
DOI 10.1210/clinem/dgaf040
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →